Defining Moments
Explore a timeline of Schrödinger’s history and the moments that shaped our company
Explore a timeline of Schrödinger’s history and the moments that shaped our company
For more than 30 years, Schrödinger has continually invested in R&D to develop and advance our scientific platform. That steadfast commitment to rigorous science supports our mission to improve human health and quality of life by transforming the way therapeutics and materials are discovered.
Today, our platform is deployed by users worldwide to enable the discovery of novel therapeutics and materials more rapidly, at a lower cost, and we believe with a higher likelihood of success.
At Schrödinger, you’ll be part of a global team of more than 800 individuals dedicated to improving the health and quality of human life, armed with the knowledge that your work makes a difference in the world, and that your discovery might just be the next big scientific breakthrough.
Co-founders Richard Friesner and Bill Goddard launch Schrödinger
First software sale to Brookhaven National Laboratory
Release of Glide, which offers high-throughput virtual screening of millions of compounds
Release of Prime, a fully integrated protein structure prediction program
Release of WaterMap, the first rigorous method for computing protein-bound water locations and energies
Co-founding of Nimbus Therapeutics with Atlas Ventures
Signed collaboration with Agios, resulting in two FDA-approved cancer medicines
Launch of Materials Science business
Release of FEP+, the first benchmark method for accurately predicting binding affinity differences among molecules with a common core
Release of LiveDesign, a next-generation enterprise informatics platform for collaborative drug design
Launch of Cryo-EM initiative to join global research centers in leveraging cryo-electron microscopy
Initial Public Offering
Launch of multi-target drug discovery, development, and commercialization collaboration with Bristol Myers Squibb
Schrödinger initiates its first clinical trial for a wholly-owned program, SGR-1505
Takeda acquisition of Nimbus TYK2 program for the $4B upfront and $2B in potential future payments